Yamo Pharmaceuticals, a clinical-stage pharmaceutical company which has developed L1-79, an oral treatment that appears to impact the core symptoms of autism, including socialization and communication.
In 2016, Yamo Pharmaceuticals completed a preliminary 12-week open label trial of L1-79 by physicians with long-standing relationships with eight treated patients of various ages (from toddler to adult), utilizing a structured protocol with validated psychometric testing to assess the results.
In 2017, Yamo Pharmaceuticals completed a randomized, double-blind, placebo-controlled 4-week study in 42 male patients (13 to 21 years of age) with autism.
In May 2018, Yamo Pharmaceuticals was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) based on study results to-date.
Yamo Pharmaceuticals is currently preparing for a 250-patient Phase 2b study under FDA oversight that is planned to start treating patients in early 2019.
Anyone interested in learning more about Yamo Pharmaceuticals, L1-79 and/or participation in future clinical studies may contact us directly.